Kezar Life Sciences, Inc. (KZR) Other Accumulated Expenses (2017 - 2023)

Kezar Life Sciences has reported Other Accumulated Expenses for 7 years, with the latest figure at $106000.0 in Q4 2023.

• Quarterly Other Accumulated Expenses fell 60.0% year-over-year to $106000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $106000.0 (down 60.0% YoY) and the FY2023 annual result came in at $106000.0, down 60.0% from the prior year.
• Other Accumulated Expenses retreated to $106000.0 in Q4 2023 per KZR's latest filing, from $265000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $280000.0 in Q3 2021 and troughed at $21000.0 in Q4 2020.
• A 5-year average of $133071.4 and a median of $106000.0 in 2019 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2020 and 2021: Other Accumulated Expenses slumped 86.71% in 2020, then surged 803.23% in 2021.
• Over 5 years, Other Accumulated Expenses stood at $158000.0 in 2019, then plunged by 86.71% to $21000.0 in 2020, then surged by 371.43% to $99000.0 in 2021, then surged by 167.68% to $265000.0 in 2022, then slumped by 60.0% to $106000.0 in 2023.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $106000.0, $265000.0, and $99000.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.